Loading...

Tandem Diabetes Care

Nasdaq:TNDM
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TNDM
Nasdaq
$4B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Tandem Diabetes Care has significant price volatility in the past 3 months.
TNDM Share Price and Events
7 Day Returns
-6%
NasdaqGM:TNDM
-1.5%
US Medical Equipment
-1.1%
US Market
1 Year Returns
1623.3%
NasdaqGM:TNDM
24.7%
US Medical Equipment
6.4%
US Market
TNDM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tandem Diabetes Care (TNDM) -6% 42.3% 114.1% 1623.3% -13% -67.6%
US Medical Equipment -1.5% 1.7% 18.7% 24.7% 70.4% 95.9%
US Market -1.1% 0.3% 16.7% 6.4% 37.9% 42.1%
1 Year Return vs Industry and Market
  • TNDM outperformed the Medical Equipment industry which returned 24.7% over the past year.
  • TNDM outperformed the Market in United States of America which returned 6.4% over the past year.
Price Volatility
TNDM
Industry
5yr Volatility vs Market

Value

 Is Tandem Diabetes Care undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tandem Diabetes Care to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tandem Diabetes Care.

NasdaqGM:TNDM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:TNDM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.931 (1 + (1- 21%) (0%))
0.954
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.954 * 5.96%)
8.41%

Discounted Cash Flow Calculation for NasdaqGM:TNDM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tandem Diabetes Care is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:TNDM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.41%)
2019 -3.31 Analyst x3 -3.05
2020 21.74 Analyst x3 18.50
2021 51.71 Analyst x2 40.58
2022 81.68 Est @ 57.98% 59.13
2023 115.51 Est @ 41.4% 77.12
2024 149.93 Est @ 29.8% 92.33
2025 182.44 Est @ 21.68% 103.63
2026 211.62 Est @ 16% 110.88
2027 237.04 Est @ 12.02% 114.56
2028 258.92 Est @ 9.23% 115.42
Present value of next 10 years cash flows $729.08
NasdaqGM:TNDM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $258.92 × (1 + 2.73%) ÷ (8.41% – 2.73%)
$4,678.93
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,678.93 ÷ (1 + 8.41%)10
$2,085.72
NasdaqGM:TNDM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $729.08 + $2,085.72
$2,814.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,814.80 / 57.72
$48.77
NasdaqGM:TNDM Discount to Share Price
Calculation Result
Value per share (USD) From above. $48.77
Current discount Discount to share price of $68.76
= -1 x ($68.76 - $48.77) / $48.77
-41%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Tandem Diabetes Care is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tandem Diabetes Care's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tandem Diabetes Care's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:TNDM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.55
NasdaqGM:TNDM Share Price ** NasdaqGM (2019-03-22) in USD $68.76
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 38.72x
United States of America Market PE Ratio Median Figure of 3,061 Publicly-Listed Companies 17.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tandem Diabetes Care.

NasdaqGM:TNDM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TNDM Share Price ÷ EPS (both in USD)

= 68.76 ÷ -2.55

-26.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tandem Diabetes Care is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Tandem Diabetes Care is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Tandem Diabetes Care's expected growth come at a high price?
Raw Data
NasdaqGM:TNDM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -26.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
82%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 53 Publicly-Listed Medical Equipment Companies 2.58x
United States of America Market PEG Ratio Median Figure of 2,104 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tandem Diabetes Care, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tandem Diabetes Care's assets?
Raw Data
NasdaqGM:TNDM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.28
NasdaqGM:TNDM Share Price * NasdaqGM (2019-03-22) in USD $68.76
United States of America Medical Equipment Industry PB Ratio Median Figure of 188 Publicly-Listed Medical Equipment Companies 4.48x
United States of America Market PB Ratio Median Figure of 5,164 Publicly-Listed Companies 1.84x
NasdaqGM:TNDM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TNDM Share Price ÷ Book Value per Share (both in USD)

= 68.76 ÷ 2.28

30.15x

* Primary Listing of Tandem Diabetes Care.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tandem Diabetes Care is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Tandem Diabetes Care's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Tandem Diabetes Care has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Tandem Diabetes Care expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
82%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tandem Diabetes Care expected to grow at an attractive rate?
  • Tandem Diabetes Care's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Tandem Diabetes Care's earnings growth is expected to exceed the United States of America market average.
  • Tandem Diabetes Care's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:TNDM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:TNDM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 82%
NasdaqGM:TNDM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 21.3%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.4%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:TNDM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:TNDM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 626 31 2
2022-12-31 518 10 4
2021-12-31 415 59 -4 6
2020-12-31 335 25 -25 12
2019-12-31 267 -2 -43 12
NasdaqGM:TNDM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 184 -8 -123
2018-09-30 148 -34 -138
2018-06-30 129 -50 -119
2018-03-31 116 -58 -82
2017-12-31 108 -66 -73
2017-09-30 96 -68 -76
2017-06-30 82 -67 -90
2017-03-31 83 -66 -87
2016-12-31 84 -61 -83
2016-09-30 84 -58 -81
2016-06-30 88 -54 -70
2016-03-31 81 -59 -72

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tandem Diabetes Care's earnings are expected to grow significantly at over 20% yearly.
  • Tandem Diabetes Care's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:TNDM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Tandem Diabetes Care Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TNDM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.49 0.49 0.49 1.00
2022-12-31 -0.18 -0.18 -0.18 1.00
2021-12-31 -0.06 0.17 -0.52 5.00
2020-12-31 -0.40 -0.26 -0.68 9.00
2019-12-31 -0.71 -0.44 -0.88 9.00
NasdaqGM:TNDM Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.55
2018-09-30 -3.82
2018-06-30 -5.10
2018-03-31 -8.74
2017-12-31 -12.86
2017-09-30 -18.54
2017-06-30 -25.15
2017-03-31 -28.01
2016-12-31 -27.30
2016-09-30 -26.55
2016-06-30 -23.30
2016-03-31 -23.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Tandem Diabetes Care is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Tandem Diabetes Care's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tandem Diabetes Care has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Tandem Diabetes Care performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tandem Diabetes Care's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tandem Diabetes Care does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Tandem Diabetes Care's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tandem Diabetes Care's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Tandem Diabetes Care's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tandem Diabetes Care Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TNDM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 183.87 -122.61 105.23 29.23
2018-09-30 147.96 -137.71 94.35 26.18
2018-06-30 128.70 -119.49 84.97 23.10
2018-03-31 115.90 -81.93 84.44 21.51
2017-12-31 107.60 -73.03 86.38 20.66
2017-09-30 96.22 -76.45 84.14 19.26
2017-06-30 81.51 -90.23 84.70 20.50
2017-03-31 83.17 -86.76 83.69 19.77
2016-12-31 84.25 -83.45 82.83 18.81
2016-09-30 84.46 -80.71 84.31 18.60
2016-06-30 87.88 -70.49 82.75 17.54
2016-03-31 80.60 -71.69 81.26 17.27
2015-12-31 72.85 -72.42 78.62 16.96
2015-09-30 61.62 -78.79 78.19 16.75
2015-06-30 59.42 -79.11 77.97 16.16
2015-03-31 53.97 -78.77 76.44 15.99
2014-12-31 49.72 -79.52 75.12 15.79
2014-09-30 42.08 -84.67 69.31 15.22
2014-06-30 36.34 -77.83 62.42 13.36
2014-03-31 31.61 -73.94 55.68 12.42
2013-12-31 29.01 -63.14 44.52 11.08
2013-09-30 21.02 -48.08 36.18 9.72
2013-06-30 13.46 -42.53 30.64 9.18
2013-03-31 7.93 -35.70 24.44 8.88
2012-12-31 2.48 -33.02 22.69 9.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tandem Diabetes Care has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Tandem Diabetes Care has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tandem Diabetes Care improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tandem Diabetes Care's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tandem Diabetes Care has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Tandem Diabetes Care's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tandem Diabetes Care's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tandem Diabetes Care is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tandem Diabetes Care's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tandem Diabetes Care's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Tandem Diabetes Care has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tandem Diabetes Care Company Filings, last reported 2 months ago.

NasdaqGM:TNDM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 131.28 0.00 129.03
2018-09-30 115.43 0.00 113.58
2018-06-30 26.01 77.10 86.51
2018-03-31 11.85 76.41 71.88
2017-12-31 -29.15 76.54 14.18
2017-09-30 -27.96 75.60 12.54
2017-06-30 -18.28 74.68 27.79
2017-03-31 -1.87 73.76 44.01
2016-12-31 -5.93 78.96 53.54
2016-09-30 5.20 44.68 34.08
2016-06-30 32.07 44.40 54.32
2016-03-31 45.94 44.11 68.43
2015-12-31 63.47 29.28 71.11
2015-09-30 71.23 29.50 81.75
2015-06-30 87.75 29.48 97.75
2015-03-31 102.25 29.46 116.38
2014-12-31 54.57 29.44 67.28
2014-09-30 67.48 29.42 79.88
2014-06-30 83.55 29.39 94.31
2014-03-31 97.26 29.44 110.77
2013-12-31 115.54 29.40 129.48
2013-09-30 2.58 29.35 15.55
2013-06-30 9.15 29.29 30.13
2013-03-31 18.59 4.20 17.16
2012-12-31 18.59 4.20 17.16
  • Tandem Diabetes Care has no debt.
  • Tandem Diabetes Care has no debt compared to 5 years ago when it was 25.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Tandem Diabetes Care has sufficient cash runway for more than 3 years based on current free cash flow.
  • Tandem Diabetes Care has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -18.5% each year.
X
Financial health checks
We assess Tandem Diabetes Care's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tandem Diabetes Care has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Tandem Diabetes Care's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tandem Diabetes Care dividends. Estimated to be 0% next year.
If you bought $2,000 of Tandem Diabetes Care shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tandem Diabetes Care's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tandem Diabetes Care's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:TNDM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2003 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.9%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:TNDM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tandem Diabetes Care has not reported any payouts.
  • Unable to verify if Tandem Diabetes Care's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tandem Diabetes Care's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tandem Diabetes Care has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Tandem Diabetes Care's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Tandem Diabetes Care's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tandem Diabetes Care afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tandem Diabetes Care has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Tandem Diabetes Care's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Sheridan
COMPENSATION $597,093
AGE 63
TENURE AS CEO 0 years
CEO Bio

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 2013 until March 01, 2019. Mr. Sheridan served as Chief Operating Officer at Rapiscan Systems, Inc. from March 2012 to February 2013. Mr. Sheridan served as an Executive Vice President of Research and Development and Operations of Volcano Corp. from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation and led the development and manufacturing efforts for scintillator/photodiode detector system. Prior to joining Digirad Corp., from October 1983 to March 1998, Mr. Sheridan held various positions, including Director of Operations, at Analog Devices Inc., a semiconductor company that develops, manufacturers and markets high performance integrated circuits used in signal-processing applications. He holds a B.S. Degree in Chemistry from the University of West Florida and an M.B.A. from Boston University.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year.
  • John's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Tandem Diabetes Care management team in years:

3.1
Average Tenure
49
Average Age
  • The tenure for the Tandem Diabetes Care management team is about average.
Management Team

Kim Blickenstaff

TITLE
Executive Chairman of the Board
COMPENSATION
$749K
AGE
66

John Sheridan

TITLE
President & CEO
COMPENSATION
$597K
AGE
63

Brian Hansen

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$609K
AGE
50
TENURE
3.1 yrs

Leigh Vosseller

TITLE
Executive VP
AGE
45
TENURE
6.2 yrs

Manuel Jaime

TITLE
Senior Vice President of Technology & Digital Health
TENURE
0.1 yrs

Susan Morrison

TITLE
Executive VP & Chief Administrative Officer
COMPENSATION
$3M
AGE
39
TENURE
5.5 yrs

David Berger

TITLE
Executive VP
AGE
48
TENURE
5.6 yrs

Tom Fox

TITLE
Vice President of Human Resources
TENURE
1.6 yrs

Jim Leal

TITLE
Senior Vice President of Operations
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the Tandem Diabetes Care board of directors in years:

5.8
Average Tenure
62
Average Age
  • The tenure for the Tandem Diabetes Care board of directors is about average.
Board of Directors

Doug Roeder

TITLE
Independent Director
COMPENSATION
$68K
AGE
47
TENURE
9.8 yrs

Kim Blickenstaff

TITLE
Executive Chairman of the Board
COMPENSATION
$749K
AGE
66

Fred Cohen

TITLE
Independent Director
COMPENSATION
$51K
AGE
62
TENURE
5.8 yrs

Christopher Twomey

TITLE
Independent Director
COMPENSATION
$69K
AGE
59
TENURE
5.7 yrs

Dick Allen

TITLE
Lead Independent Director
COMPENSATION
$99K
AGE
74

Ted Greene

TITLE
Independent Director
COMPENSATION
$52K
AGE
75
TENURE
11.2 yrs

Ed Cahill

TITLE
Independent Director
COMPENSATION
$55K
AGE
65
TENURE
9.8 yrs

Rick Valencia

TITLE
Director
AGE
55
TENURE
0.8 yrs

Beckie Robertson

TITLE
Independent Director
AGE
57
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • Tandem Diabetes Care insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Mar 19 Sell Kim Blickenstaff Individual 11. Mar 19 11. Mar 19 -200,000 $65.67 $-12,990,444
11. Mar 19 Sell Cornerstone Ventures Inc. Company 08. Mar 19 08. Mar 19 -4,103 $63.21 $-257,753
11. Mar 19 Sell Dick Allen Individual 08. Mar 19 08. Mar 19 -13,436 $63.22 $-839,877
01. Mar 19 Sell Howard Greene Individual 28. Feb 19 28. Feb 19 -10,000 $66.21 $-653,884
03. Jan 19 Sell John Sheridan Individual 31. Dec 18 31. Dec 18 -788 $37.81 $-29,797
07. Nov 18 Sell Cornerstone Ventures Inc. Company 05. Nov 18 05. Nov 18 -3,898 $37.75 $-147,150
07. Nov 18 Sell Dick Allen Individual 05. Nov 18 05. Nov 18 -11,324 $38.11 $-431,526
07. Nov 18 Buy Richard Valencia Individual 05. Nov 18 05. Nov 18 1,300 $37.75 $49,075
07. Nov 18 Sell Howard Greene Individual 06. Nov 18 06. Nov 18 -11,787 $36.53 $-430,579
07. Nov 18 Sell Kim Blickenstaff Individual 06. Nov 18 07. Nov 18 -198,000 $37.01 $-7,327,626
03. Aug 18 Buy Richard Valencia Individual 03. Aug 18 03. Aug 18 1,754 $28.50 $49,989
X
Management checks
We assess Tandem Diabetes Care's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tandem Diabetes Care has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) A Financially Strong Company?

Stocks with market capitalization between $2B and $10B, such as Tandem Diabetes Care, Inc. … Today we will look at TNDM’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Check out our latest analysis for Tandem Diabetes Care

Simply Wall St -

Have Insiders Been Selling Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So shareholders might well want to know whether insiders have been buying or selling shares in Tandem Diabetes Care, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Tandem Diabetes Care, Inc. (NASDAQ:TNDM): Time For A Financial Health Check

However, the trade-off is TNDM will have to adhere to stricter debt covenants and have less financial flexibility. … Is TNDM growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Should You Worry About Tandem Diabetes Care Inc's (NASDAQ:TNDM) CEO Pay?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Kim Blickenstaff's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Tandem Diabetes Care Inc has a market cap of US$1.9b, and is paying total annual CEO compensation of US$749k.

Simply Wall St -

Has Tandem Diabetes Care Inc (NASDAQ:TNDM) Got Enough Cash?

Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Tandem Diabetes Care Inc (NASDAQ:TNDM) with a market-capitalization of US$2.1b, rarely draw their attention. … Don’t forget that this is a general and concentrated examination of Tandem Diabetes Care's financial health, so you should conduct further analysis. … View our latest analysis for Tandem Diabetes Care

Simply Wall St -

Breakeven On The Horizon For Tandem Diabetes Care Inc (NASDAQ:TNDM)

Tandem Diabetes Care Inc's (NASDAQ:TNDM):. … Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. … The US$1.18b market-cap posted a loss in its most recent financial year of -US$73.03m and a latest trailing-twelve-month loss of -US$81.93m leading to an even wider gap between loss and breakeven.

Simply Wall St -

Are Tandem Diabetes Care Inc (NASDAQ:TNDM) Shareholders Getting A Good Deal?

Today we will examine Tandem Diabetes Care’s ability to generate cash flows, as well as the level of capital expenditure it is expected to incur over the next couple of years, which will result in how much money goes to you. … Tandem Diabetes Care’s free cash flow (FCF) is the level of cash flow the business generates from its operational activities, after it reinvests in the company as capital expenditure. … Current +1 year Operating Cash Flow (OCF) -US$57.60M -US$35.42M OCF Growth Year-On-Year -38.51% Next Steps: Now you know to keep cash flows in mind, You should continue to research Tandem Diabetes Care to get a better picture of the company by looking at: Historical Performance: What has TNDM's returns been like over the past?

Simply Wall St -

How Financially Strong Is Tandem Diabetes Care Inc (NASDAQ:TNDM)?

How does TNDM’s operating cash flow stack up against its debt? … TNDM has sustained its debt level by about US$76.54M over the last 12 months made up of current and long term debt. … Running high debt, while not yet making money, can be risky in unexpected downturns as liquidity may dry up, making it hard to operate.Next Steps: TNDM’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Has Tandem Diabetes Care Inc (NASDAQ:TNDM) Improved Earnings Growth In Recent Times?

Below, I will examine Tandem Diabetes Care Inc's (NASDAQ:TNDM) track record on a high level, to give you some insight into how the company has been performing against its long term trend and its industry peers. … See our latest analysis for Tandem Diabetes Care Did TNDM beat its long-term earnings growth trend and its industry? … For Tandem Diabetes Care, its latest trailing-twelve-month earnings is -US$73.03M, which compared to the previous year's figure, has become less negative.

Simply Wall St -

What Are Analysts Saying About Tandem Diabetes Care Inc's (NASDAQ:TNDM) Long Term Outlook?

In December 2017, Tandem Diabetes Care Inc (NASDAQ:TNDM) announced its latest earnings update, which showed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts perceive Tandem Diabetes Care's earnings growth outlook over the next few years and whether the future looks brighter. … Check out our latest analysis for Tandem Diabetes Care Analysts' outlook for the coming year seems optimistic, with earnings becoming less negative, generating -US$60.65M in 2019. … This means, we can anticipate Tandem Diabetes Care will grow its earnings by 38.98% every year for the next few years.

Simply Wall St -

Company Info

Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump’s software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Details
Name: Tandem Diabetes Care, Inc.
TNDM
Exchange: NasdaqGM
Founded: 2006
$3,968,663,413
57,717,618
Website: http://www.tandemdiabetes.com
Address: Tandem Diabetes Care, Inc.
11075 Roselle Street,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TNDM Common Stock Nasdaq Global Market US USD 14. Nov 2013
DB TD5A Common Stock Deutsche Boerse AG DE EUR 14. Nov 2013
LSE 0M0F Common Stock London Stock Exchange GB USD 14. Nov 2013
Number of employees
Current staff
Staff numbers
653
Tandem Diabetes Care employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/24 00:31
End of day share price update: 2019/03/22 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.